wegovy

Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome (PMOS), reflecting its hormonal and metabolic nature. Research highlights its endocrine roots, impacting insulin and other hormones, not just ovaries. This reclassification aims for earlier diagnosis and better management, emphasizing metabolic health alongside reproductive concerns for affected women.

Experiencing hair loss while losing weight is a common physiological reaction as the body enters 'survival mode.' Rapid weight loss, often triggered by extreme diets or weight-loss medications, can push hair follicles into a resting phase. Let's know more about this issue.

Affordable generic versions of Ozempic and wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

Doctors in Hyderabad are alarmed by the unsupervised use of diabetes and weight-loss drugs like Ozempic for cosmetic purposes, driven by social media and peer influence. Concerns are rising as cheaper generic versions are set to launch, potentially increasing misuse and leading to serious side effects without medical supervision.

The FDA has approved a daily pill version of Novo Nordisk's wegovy, offering an oral alternative to injectable weight-loss drugs. Containing semaglutide, the pill demonstrated similar weight loss and side-effect profiles to its injectable counterpart in clinical trials. This new option aims to expand access for patients who prefer not to use injections.

wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity and related metabolic issues. Experts emphasize it's not a quick fix but a tool to improve insulin function, reduce cardiac events, and aid those with diabetes and PCOS when combined with lifestyle changes.

Novo Nordisk has launched wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targeting India's large obese population, Novo Nordisk aims to capture a significant share of the ₹576 crore anti-obesity market.

Novo Nordisk's wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449.

Novo Nordisk has launched wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.

Ozempic, Mounjaro and wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid weight loss. Ozempic is for type 2 diabetes. Mounjaro targets two hormone pathways for stronger sugar and weight control. wegovy is for obesity and related health issues. The choice depends on individual goals and medical history.

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took wegovy